Phase II study of Dovitinib in recurrent glioblastoma.

Mayur SharmaCathy SchileroDavid M PeereboomBrian P HobbsPaul ElsonGlen H J StevensKeith McCraeAndrew B NixonManmeet S Ahluwalia

Published in: Journal of neuro-oncology (2019)

Dovitinib was not efficacious in prolonging the PFS in patients with recurrent GBM irrespective of prior treatment with anti-angiogenic therapy (including bevacizumab).

Keyphrases

phase ii study
open label
locally advanced
randomized controlled trial
clinical trial
squamous cell carcinoma
bone marrow
rectal cancer